NP Life Sciences Health Industry Group Inc. (ACAT) Return on equity 2019–2023
NP Life Sciences Health Industry Group Inc. (ACAT) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-17.9%FY2023 · since FY2019: -46.3% → -17.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -17.9% | +79.7 pp |
| FY2022 | -97.6% | +74.4 pp |
| FY2021 | -172.1% | -45.8 pp |
| FY2020 | -126.2% | -79.9 pp |
| FY2019 | -46.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ACAT financial trends
ACAT RevenueACAT Net incomeACAT Net marginACAT Gross profitACAT Gross marginACAT Operating incomeACAT Operating marginACAT Operating cash flowACAT Free cash flowACAT Capital expendituresACAT Stock buybacksACAT Dividends paidACAT Total assetsACAT Total liabilitiesACAT Shareholders’ equityACAT overview →